Renal Cell Carcinoma

First-line systemic therapy in metastatic renal cell carcinoma

Earn accreditation points

Finish 5 case(s) answer 10 question(s) and Earn 1 credit.

Continue
Educational Objective: Recognise the most appropriate first-line treatment options for patients with advanced or metastatic renal cell carcinoma (RCC), as well as comprehend factors that impact the selection of first-line systemic therapy for these patients, e.g., risk group, performance status, histology, extent of disease.
Specialty: Medical oncology, Clinical oncology, (Urology)
Target Audience: Specialists (CME: basic, intermediate), Residents (senior)
Latest update: December 2023
Background:

Regulatory approval status of drugs for the treatment of advanced/metastatic RCC, mentioned in the CME courses on first- and later-line management (status 13 December 2023)

This educational platform includes case challenges with treatment options that may not be indicated for this use in your country. Please refer to your local prescribing information.